Research programme: adenovector-based therapeutics and vaccines - GenVec/Washington University at St. Louis
Latest Information Update: 09 Jan 2017
At a glance
- Originator GenVec; Washington University
- Developer GenVec
- Class Antibodies; Vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Haemophilia